Skip to main content

Table 1 Baseline characteristics.

From: Effectiveness and safety of HAART regimens containing tenofovir DF + saquinavir or fosamprenavir in HIV patients: sub-analysis from PROTECTION study

 

FPV Cohort (n = 105)

SQV Cohort (n = 98)

% Male

74%

65%

Mean Age (years)

43

41

Primary HIV risk factor (%)

IVDU (53%)

IVDU (53%)

CDC C status (%)

44%

34%

Main reasons for TDF based regimen (%)

Virological failure (59%)

Virological failure (48%)

 

Toxicity management (19%)

Simplification (20%)

Previous time on ARV; Months. Median (IQR)

70 (21–111)

73 (34–111)

Most common acompanying NRTIs

3TC or FTC (36%)

3TC or FTC (65%)

 

AZT or d4T (26%)

AZT or d4T (7%)

 

ddI (11%)

ddI (13%)

Median BL HIV RNA, c/mL (log)

3.9

3.3

Mean BL CD4 count (cell/mm3)

335

387

  1. BL = Baseline; ARV = antiretrovirals.